MET and melanoma: While the combination of RT with Crizotinib and the combination of RT with Olaparib significantly reduced cell survival in both melanoma lines (HBL, MM162) compared to RT alone (Figure 4A), it was more efficient with the dual targeting of c-Met and PARP-1 and could prevent any residual colony formation as compared to RT + Olaparib or RT + Crizotinib (Figures 4A,B).